Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;7(9):1011-22.
doi: 10.2217/imt.15.66. Epub 2015 Sep 1.

Modulatory effects of bortezomib on host immune cell functions

Samuel Troy Pellom Jr  1   2   3 , Duafalia Fred Dudimah  1 , Menaka Chanu Thounaojam  1 , Thomas Joseph Sayers  4   5 , Anil Shanker  1   2   6
Affiliations
Review

Modulatory effects of bortezomib on host immune cell functions

Samuel Troy Pellom Jr et al. Immunotherapy. 2015.

Abstract

Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growth and diminish apoptosis. Along with inhibiting the proteasome and thus sensitizing tumor cells to apoptosis, bortezomib may also have multiple effects on the host immune responses. This review summarizes the effects that bortezomib may play on immune cell subsets in various disease states in modifying lymphocyte receptors, ligands, the expression of various cytokines and chemokines and their downstream signaling. We also propose steps that can be taken to refine combinatorial strategies that include bortezomib to improve current immunotherapeutic approaches.

Keywords: B cells; NK cells; T cells; bortezomib; chemokine; cytokine; dendritic cells; immunity; inflammation; ligands; lymphocyte receptors.

PubMed Disclaimer

References

    1. Pellom ST, Jr, Shanker A. Development of proteasome inhibitors as therapeutic drugs. J. Clin. Cell Immunol. 2012;S5:5. - PMC - PubMed
    1. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat. Rev. Mol. Cell Biol. 2005;6(1):79–87. - PubMed
    1. Hershko A, Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 1998;67:425–479. - PubMed
    1. Xie Y. Structure, assembly and homeostatic regulation of the 26s proteasome. J. Mol. Cell Biol. 2010;2(6):308–317. - PubMed
    1. Driscoll JJ, Dechowdhury R. Therapeutically targeting the sumoylation, ubiquitination and proteasome pathways as a novel anticancer strategy. Target Oncol. 2010;5(4):281–289. - PubMed

Publication types

MeSH terms

LinkOut - more resources